Skip to main content
. 2013 Dec 11;3(1):91–100. doi: 10.1002/cam4.161

Figure 2.

Figure 2

(A) Overall survival (OS) and (B) event-free survival (EFS) of ATRT patients treated according to the MUV-ATRT regimen versus other therapy protocols. OS after 1 year was 100% (MUV) versus 46.2 ± 13.8% (other), after 3 years 100% (MUV) versus 38.5 ± 13.5% (other), and after 5 years 100% (MUV) versus 28.8 ± 13.1% (other). EFS after 1 year was 100% (MUV) versus 46.2 ± 13.8% (other), after 3 years 88.9 ± 10.5% (MUV) versus 38.5 ± 13.5% (other), and after 5 years 88.9 ± 10.5% (MUV) versus 28.8 ± 13.1% (other). MUV-ATRT, Medical University of Vienna ATRT-protocol; ATRT, atypical teratoid rhabdoid tumor.